HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI
2.6.2026 14:38:00 CEST | Business Wire | Press release
Collaboration will accelerate the evolution of Xsolis’ Dragonfly platform, improving how healthcare providers and payers make faster, more aligned care decisions
HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/

HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers.
Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manual, and often inconsistent process. Known as utilization management, this function sits at the heart of healthcare operations—but is still heavily reliant on fragmented data, manual reviews, and subjective judgment. The result is delays in care, administrative burden, rising costs, and friction between providers and payers.
Xsolis addresses these challenges through its Dragonfly® platform, which uses real-time patient data, machine learning, and predictive analytics to bring greater objectivity, speed, and transparency to decision-making. By continuously analysing patient condition and care requirements, the platform helps healthcare organizations align faster on medical and care decisions while reducing operational inefficiencies, administrative waste, and friction between providers and payers.
Through this partnership, HTEC will play a central role in advancing the Dragonfly platform—bringing deep expertise in AI-enabled product engineering and software development lifecycle (SDLC), as well as scalable cloud-based systems and AI tooling.
HTEC will support the continued evolution of the platform’s predictive capabilities across key healthcare workflows, including utilization management, discharge readiness prediction, appeals and denials management, and operational analytics for providers and payer organizations. The collaboration will focus on embedding agentic AI to improve workflow automation, accelerate data-driven decision-making, and enhance operational intelligence, while modernizing the underlying engineering environment to speed innovation and ensure compliance with strict healthcare regulations.
A key differentiator of the partnership is HTEC’s AI-powered approach to software delivery. By embedding AI across the end-to-end SDLC—from translating product requirements and generating specifications to accelerating development, QA, code review, and delivery tracking—HTEC helps organizations improve engineering efficiency, increase release velocity, and bring new capabilities to market faster. Working closely with Xsolis, HTEC will help identify and implement the right AI-enabled engineering practices and tooling to streamline product development while maintaining the reliability, transparency, and compliance required in healthcare technology environments.
“Xsolis is addressing some of healthcare’s most operationally complex challenges through AI-driven clinical and operational decision support,” said Lawrence Whittle, Chief Strategy Officer at HTEC. “We’re excited to bring our healthcare engineering expertise and AI-first delivery approach to support the continued evolution of the Dragonfly platform. Together, we aim to help healthcare organizations operate more efficiently while enabling better experiences for providers, payers, and patients.”
“HTEC stood out because of its strong engineering culture, healthcare domain expertise, and practical approach to applying AI across both product innovation and software delivery,” said Zach Evans, CTO at Xsolis. “As we continue to expand the Dragonfly platform, we see HTEC as a strategic partner that can help accelerate innovation while maintaining the reliability, compliance, and operational excellence our customers expect.”
The collaboration reflects a shared commitment to solving one of healthcare’s most pressing challenges: how to deliver faster, more aligned care decisions at scale while reducing cost and complexity. By combining Xsolis’ AI-driven decision intelligence with HTEC’s ability to engineer, scale, and operationalise advanced AI systems, the partnership is positioned to deliver measurable impact across healthcare organizations.
About Xsolis
Xsolis is an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Dragonfly®, its AI-driven proprietary platform, is the first and only solution to use real-time predictive analytics to continuously assign an objective medical necessity score and assess the anticipated level of care for every patient, enabling more efficiency across the healthcare system. Xsolis is headquartered in Franklin, Tennessee. For more information, visit www.xsolis.com.
About HTEC
HTEC Group Inc. is a global AI-first provider of complex software and hardware embedded design and engineering services, specializing in Advanced Technologies, Financial Services, MedTech, Automotive, Telco, and Enterprise Software & Platforms. HTEC has a proven track record of helping Fortune 500 and hyper-growth companies solve complex engineering challenges, drive efficiency, reduce risks, and accelerate time to market. HTEC prides itself on attracting top talent and has strategically chosen the locations of its 20+ excellence centers to enable this.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260602462348/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Celltrion Expands Omlyclo® Portfolio in Europe with Launch of 300 mg Strength25.8.2026 00:40:00 CEST | Press release
Omlyclo® (omalizumab) 300 mg launched in key European markets including Germany, the UK and France, with rollout to expand across Europe by year-endOmlyclo® 300 mg strength available in both pre-filled syringe (PFS) and autoinjector (AI) presentationsMultiple dose strengths and device options broaden treatment flexibility for healthcare professionals Celltrion (KRX: 068270) today announced the launch of the 300 mg strength of Omlyclo® (omalizumab), a treatment for chronic spontaneous urticaria and allergic asthma, in Europe.1 With the addition of the 300 mg strength, Celltrion has expanded its Omlyclo® portfolio to include multiple dose strengths and device presentations for patients, healthcare professionals and healthcare institutions. Following the European launch of Omlyclo® 75 mg and 150 mg late last year, Celltrion began rolling out the 300 mg strength in key markets including Germany, the UK and France in the middle of this year. Celltrion is gradually expanding supply to other
Fourthline Trust Services Granted Status as Qualified Trust Service Provider in the EU24.8.2026 15:13:00 CEST | Press release
QTSP status allows for full control over the digital trust value chain from identity verification to qualified electronic signature (QES) issuance Fourthline Trust Services AB, a subsidiary of Fourthline, has been granted qualified status under the EU's eIDAS Regulation (910/2014)¹ and is now listed on the EU Trusted List as a Qualified Trust Service Provider (QTSP). Supervised by the Swedish Post and Telecom Authority (Post- och telestyrelsen, PTS), Fourthline Trust Services AB issues qualified certificates for electronic signatures. Fourthline, is the leading European provider of AI-powered identity verification (IDV) and compliance solutions. This milestone allows Fourthline full control over the entire digital trust value chain from identity verification to qualified electronic signature (QES) issuance. Ralph Post, Fourthline Trust Services AB Board Member: "By building our QTSP infrastructure similar to our sovereign AI-powered platform that drives our industry-leading identity ve
SLB Launches ExaCT Electrical Downhole CT Control System24.8.2026 13:02:00 CEST | Press release
New platform brings real-time electrical control to coiled tubing intervention, enabling greater precision, visibility and efficiency across intervention operations SLB (NYSE: SLB) today launched the ExaCT™ electrical downhole coiled tubing (CT) control system, an advanced intervention platform that introduces real-time electrical control to coiled tubing operations. By replacing pressure-dependent hydraulic actuation with electrical communication, power delivery and telemetry, the ExaCT system gives operators greater visibility, precision and control, helping improve intervention execution and reservoir access. The ExaCT system combines electrical power, telemetry and downhole measurements to enable communication with, actuation of and verification of downhole tools throughout an intervention. Continuous communication across the toolstring enables on-demand tool actuation across a wide range of intervention applications, including extended-reach and multilateral wells. The increased p
Wolters Kluwer Transforms Trusted Legal Content Into Structured, AI-Ready Intelligence That Powers the Next Wave of Legal AI24.8.2026 13:01:00 CEST | Press release
By transforming authoritative legal content into structured legal intelligence, Wolters Kluwer gives AI the context and relationships needed to deliver deeper research and higher-quality results Wolters KluwerLegal & Regulatory today announced the next evolution of Libra by Wolters Kluwer, its all-in-one Legal AI Workspace. By transforming authoritative legal sources, expert commentaries, and practical guidance into structured legal intelligence, Wolters Kluwer is making the relationships across the full breadth of its expert legal sources more explicit. This will enable deeper contextual research, more comprehensible answers, and workflow-ready results across legal work. Following the integration of Wolters Kluwer content into the Libra AI workspace in the first half of 2026, laws, rulings, expert commentaries, and practical guidance will now be linked to one another and to the matter at hand, creating a connected knowledge graph of expert-curated and authoredlegal knowledge that AI c
Daiichi Sankyo Appoints Markus Kosch to Lead Europe Business as Part of New Commercialization Organization24.8.2026 10:00:00 CEST | Press release
Daiichi Sankyo (TSE: 4568) today announced the appointment of Markus Kosch, MD, as Head of Europe Business, effective April 1, 2027. In this role, he will lead the company's European business within the new globally integrated Commercialization Unit and serve as General Manager of Daiichi Sankyo Europe GmbH, with legal responsibility for the company in Europe. The appointment reflects the next phase of growth of Daiichi Sankyo under its Five-Year Business Plan and the establishment of a new Commercialization Unit. Within this new structure, Markus Kosch will bring together the Oncology and Specialty businesses in Europe under one integrated leadership model to help bring innovative medicines to more patients across the region. For the past five years, Markus Kosch has led the Daiichi Sankyo Oncology Business Division in Europe and Canada, overseeing a period of significant growth and preparing the organization for an increasingly expanding oncology portfolio. Prior to joining Daiichi S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom